The Global Pharmaceutical-grade HFA-134a Market was valued at USD 752 Million in 2025 and is projected to reach USD 1,242 Million by 2034, growing at a Compound Annual Growth Rate (CAGR) of 7.7% during the forecast period (2024–2034). This robust growth is driven by the rising global prevalence of chronic respiratory diseases like asthma and COPD, the global phase-out of CFC-based propellants, and stringent regulatory standards mandating high-purity, non-ozone-depleting alternatives for inhaled drug delivery.

As the pharmaceutical industry continues its critical mission to improve patient outcomes and accessibility, the demand for reliable, high-purity propellants is escalating. This blog profiles the Top 10 Companies in the Pharmaceutical-grade HFA-134a Industry—a group of specialized chemical manufacturers and fluorochemical giants ensuring the safe and effective delivery of life-saving respiratory medications worldwide.

Download FREE Sample Report:
Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

🔟 1. SRF Limited

Headquarters: Gurugram, Haryana, India
Key Offering: High-purity HFA-134a (≥99.99%) for Metered-Dose Inhalers (MDIs)

SRF Limited is a leading global manufacturer of industrial and specialty chemicals, with a formidable presence in the fluorochemicals sector. The company is recognized as a major global supplier of Pharmaceutical-grade HFA-134a, adhering to stringent pharmacopoeial standards (USP/EP). Its products are critical components for major pharmaceutical companies developing inhalers for asthma and COPD treatments.

Strategic Initiatives:

• Significant investment in expanding fluorochemical production capacity to meet rising global demand.

• Strong focus on R&D to enhance purity levels and develop next-generation propellant formulations.

• Strategic partnerships with global pharmaceutical giants to ensure a stable supply chain for MDI manufacturers.

---

9️⃣ 2. Koura (A GC company)

Headquarters: Manchester, United Kingdom
Key Offering: Zephex® 134a (Pharmaceutical Grade HFA-134a)

Koura, a global leader in the manufacture and supply of fluoroproducts, is a key player in the pharmaceutical propellants market. Its Zephex® 134a is a high-purity product specifically designed for use in pressurized MDIs. Koura operates one of the world’s largest fluorochemical production sites, ensuring a reliable and scalable supply for the healthcare industry.

Strategic Initiatives:

• Continuous process innovation to achieve superior purity and consistency.

• Proactive engagement with regulatory bodies to shape industry standards for inhaler propellants.

• Global distribution network tailored to serve the pharmaceutical industry’s just-in-time needs.

---

8️⃣ 3. Zhejiang Juhua Co., Ltd. (Juhua Shares)

Headquarters: Quzhou, Zhejiang, China
Key Offering: Pharmaceutical-grade HFA-134a, HFA-227ea

Zhejiang Juhua is one of China’s largest fluorochemical producers and a significant supplier in the Asian pharmaceutical propellant market. The company has developed advanced purification technologies to produce HFA-134a that meets international pharmacopoeia standards, catering to the rapidly growing domestic and regional demand for respiratory therapeutics.

Strategic Initiatives:

• Aggressive capacity expansion to capitalize on the Asia-Pacific market growth.

• Investment in vertical integration to secure raw material supply and control costs.

• Focus on increasing exports to emerging markets in Southeast Asia and the Middle East.

---

7️⃣ 4. The Chemours Company

Headquarters: Wilmington, Delaware, USA
Key Offering: Opteon™ and Freon™ branded fluorochemicals, including high-purity grades for pharmaceuticals.

As a spin-off from DuPont, Chemours possesses deep expertise in fluoroproducts. While widely known for its refrigerants, the company also supplies high-purity materials suitable for specialized applications, including pharmaceutical propellants. Their technical expertise and large-scale manufacturing capabilities make them a formidable indirect player and potential future leader.

Strategic Initiatives:

• R&D focused on sustainable fluorochemical solutions and advanced purification techniques.

• Leveraging existing refrigerant supply chains for potential entry into the pharmaceutical-grade segment.

Download FREE Sample Report:
Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

6️⃣ 5. Daikin Industries, Ltd.

Headquarters: Osaka, Japan
Key Offering: High-purity fluorochemicals for various industrial and electronic applications.

Daikin, a global powerhouse in air conditioning and fluorochemicals, has the technical capability to produce ultra-high-purity HFA-134a. Its extensive research in fluorine chemistry positions it as a key supplier for demanding applications, with potential for significant market share in the pharmaceutical sector as demand escalates.

Strategic Initiatives:

• Exploration of specialized, high-value segments within the fluorochemical market, including pharmaceuticals.

• Investment in production technologies that ensure exceptional product purity and low impurity levels.

---

5️⃣ 6. Arkema S.A.

Headquarters: Colombes, France
Key Offering: Forane® F134A and other high-performance fluorogases.

Arkema is a leading European specialty chemicals company with a strong fluorochemicals division. The company produces Forane® F134A, which, while primarily for refrigeration, showcases the company’s capability to manufacture HFA-134a. Arkema’s commitment to innovation and specialty segments makes it a notable participant in the broader ecosystem.

Strategic Initiatives:

• Strategic focus on developing sustainable and high-performance materials.

• Strong R&D pipeline that could be directed toward pharmaceutical-grade purification processes.

---

4️⃣ 7. Dongyue Group Limited

Headquarters: Zibo, Shandong, China
Key Offering: A comprehensive range of fluorochemicals, including HFC-134a.

Dongyue Group is a major Chinese chemical company with one of the most integrated fluorochemical industrial chains in the world. It is a large-volume producer of HFC-134a and has the potential to become a key supplier of pharmaceutical-grade material, especially for the cost-sensitive Asian and African markets.

Strategic Initiatives:

• Continuous expansion of production scale to achieve economies of scale.

• Investment in upgrading purification facilities to meet international pharmaceutical standards.

---

3️⃣ 8. Honeywell International Inc.

Headquarters: Charlotte, North Carolina, USA
Key Offering: Solstice® and Genetron® refrigerants, including HFOs and HFAs.

Honeywell is a diversified technology and manufacturing leader. ItsPerformance Materials and Technologies segment is a key player in the fluorochemical space. Honeywell’s advanced materials expertise and global footprint position it as a critical supplier of high-purity gases, with capabilities relevant to the pharmaceutical propellant market.

Strategic Initiatives:

• Pioneering the development of next-generation, low-global-warming-potential hydrofluoroolefins (HFOs).

• Maintaining stringent quality control systems applicable to pharmaceutical supply chains.

---

2️⃣ 9. Linde plc

Headquarters: Guildford, United Kingdom
Key Offering: Ultra-high-purity specialty gases and gas handling equipment.

Linde, a global leader in industrial gases and engineering, plays a crucial role in the supply chain for high-purity chemicals. While not a primary manufacturer of HFA-134a, Linde’s expertise in purification, analysis, and packaging of specialty gases is essential for ensuring the final product meets pharmacopoeial specifications for moisture and impurities.

Strategic Initiatives:

• Providing critical purification and quality verification services to propellant manufacturers.

• Developing advanced gas delivery systems for pharmaceutical manufacturing facilities.

---

1️⃣ 10. Navin Fluorine International Limited

Headquarters: Mumbai, Maharashtra, India
Key Offering: Specialty fluorination services and high-value fluorochemicals.

Navin Fluorine is a respected Indian company specializing in complex fluorination chemistry. It has a strong contract research and manufacturing (CRAMS) business catering to the pharmaceutical industry. This expertise makes it a strategic partner for developing and producing specialty fluorinated molecules and high-purity ingredients, including propellants.

Strategic Initiatives:

• Leveraging its CRAMS model to partner with pharma companies on custom propellant solutions.

• Investing in new capabilities to produce and purify complex fluorinated compounds under cGMP standards.

Get Full Report Here:
Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

---

🌍 Outlook: The Future of Pharmaceutical-grade HFA-134a Is Driven by Health and Sustainability

The Pharmaceutical-grade HFA-134a market is on a steady growth trajectory, underpinned by its indispensable role in global healthcare. The ongoing transition from CFCs, coupled with the increasing global burden of respiratory diseases, ensures sustained demand. However, the future will also be shaped by evolving environmental regulations and the search for next-generation solutions.

📈 Key Trends Shaping the Market:

• Rising Disease Prevalence: Increasing incidence of asthma, COPD, and other respiratory conditions, particularly in emerging economies with high pollution levels, is a primary market driver.

• Stringent Regulatory Compliance: Mandates from the FDA, EMA, and other agencies for high-purity, environmentally compliant propellants continue to favor HFA-134a over older alternatives.

• Innovation in Inhaler Technology: Development of new drug formulations and inhaler device designs that optimize the use of HFA-134a for improved drug delivery and patient compliance.

• Geographic Market Expansion: Strong growth potential in the Asia-Pacific region, driven by improving healthcare access, large patient populations, and local manufacturing expansion.

Get Full Report Here:
Pharmaceutical-grade HFA-134a Market – View in Detailed Research Report

The companies profiled above are at the forefront of ensuring a stable and high-quality supply of a critical component in modern medicine. They are not just chemical suppliers; they are enablers of respiratory health for millions of patients worldwide, playing a vital role in the global healthcare ecosystem.